Company intelligence / Profile preview

ImmuneBiotech

Ownership: Private
Development stage: Other

Overview

ImmuneBiotech has developed a proprietary platform to design precision probiotic consortia targeting the gut microbiome and immune system. Its lead product, GutMagnific®, has shown promising results in investigator-led clinical studies for IBS, CDI, and ME/CFS. The company’s pipeline includes preclinical programs addressing additional chronic inflammatory and infectious diseases. Clinical data from hospital exemption use and academic collaborations indicate meaningful patient improvements; formal publication of results from recent studies with Karolinska Institute are pending.

Therapeutic areas: GastroenterologyNeurologyInfectious Diseases
Modalities: Live biotherapeutic product therapyMicrobial therapyProbiotic therapy (precision probiotics)Synbiotic formulations
Industry: Biotech

Beyond the preview

Go deeper on ImmuneBiotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmuneBiotech.

Explore the full profile